Lung Cancer

A lung nodule is a small growth on the lung and can be benign or malignant. The growth usually has to be smaller than 3 centimeters to qualify as a nodule. Benign nodules are noncancerous, typically not aggressive, and do not spread to other parts of the body. Malignant nodules are cancerous and can grow quickly. They can spread to other nearby tissues and distant organs. Doctors usually call growths that are larger than 3 centimeters (cm) lung masses, and these typically have a higher chance of being cancerous. In this article, we look at the possible causes of lung nodules, their symptoms, and how doctors diagnose and treat them. Although the diagnosis of any growth in the lung can be frightening, a lung nodule does not always indicate lung cancer. Lung nodules are very common. According to the American Thoracic Society, lung nodules are visible on up to 50% of chest CT scans in adults. Fewer than 5% of lung nodules end up being cancer. Noncancerous lung nodules can have a variety of...

Perceptions about lung cancer have long been shaped by the prevalence of smoking as a heavy predictor of disease, but doctors have grown increasingly concerned about a growing number of cancer cases among non-smokers. Many of these new diagnoses are the consequence of a very different disease progression than the telltale signs seen in long-term smokers. Often hard to detect, they stem from a medical finding known as ground glass opacities (GGOs), which are hazy-looking spots in the lungs that show up on CAT scans. "This is rapidly becoming one of the biggest problems that we're finding on CAT scans," said Dr. Sunil Singhal, Director of the Center for Precision Surgery at Penn Medicine's Abramson Cancer Center and Chief of the Division of Thoracic Surgery. Oncologists who treat lung cancer in smokers are accustomed to seeing solid, well-defined lesions in the lungs that are frequentl...

Lung cancer is the leading cause of cancer deaths across the globe, according to Mayo Clinic. Though smokers are at a higher risk of developing lung cancer, but it can also affect non-smokers. Risk of lung cancer increases with the duration of smoking and the number of cigarrettes you smoke on a daily basis. Headaches, hoarseness, loss of breath, blood while coughing, non-stop coughing, pain in the bones are few common symptoms of lung cancer. There are various options for treating lung cancer. But today we shall pay attention to the ways that can help prevent lung cancer.

The severity of a person's BPH symptoms will determine their treatment options. If the condition is negatively affecting the person's quality of life, doctors may prescribe medications, such as alpha-blockers and 5-alpha reductase inhibitors, or even surgical intervention. Alpha-blockers help reduce BPH symptoms by relaxing muscles in the urethra and the neck of the bladder, which can improve urine flow. The drug 5-alpha reductase converts testosterone into dihydrotestosterone (DHT). DHT is an androgen that prevents the death of prostate cells and promotes their proliferation. Through these effects, it increases the size of the prostate gland. Inhibiting the production of this androgen can help slow or stop prostate growth. Learn more about BPH, including its symptoms and medical treatments. However, some people may wish to try natural remedies for BPH. Those wishing to try these remedies should consult a doctor or an integrative medicine physician first, if possible. 1. Saw pa...

Treatment with the androgen receptor inhibitor, darolutamide (Nubeqa) led to a reduction in local urinary and bowel symptoms as well as a delay in the deterioration in the quality of life (QOL) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated in the phase 3 ARAMIS clinical trial (NCT02200614). In the primary analysis of ARAMIS, darolutamide demonstrated improvement in both metastasis-free survival (MFS) and overall survival (OS). Investigators then set out to determine the relationship between prostate-specific antigen (PSA) response and urinary and bowel adverse events (AEs), QOL deterioration, and prostate cancer-related invasive procedures. Patients included in the analysis were randomized 2:1 to receive either darolutamide (n = 955) or placebo (n = 554) both with androgen deprivation therapy (ADT). The impact of PSA response was determined by declines for baseline to week 16. Investigators used the European Organization for Research and Treatment of ...

This simple test at home can help you determine your risk of skin cancer. It takes just two minutes. All you have to do is roll your sleeves up on your cardigan or shirt. 6 Skin cancer risk can be identified by counting the moles on your arms Credit: Getty There are many types of skin cancers that fall under the umbrella of non-melanoma or melanoma. Non-melanoma skin tumors are diagnosed an average of 147,000 times per year in the UK. They grow in the upper skin layers.  Melanoma, which is less common than other types, is diagnosed approximately 16,000 times per year. However, it is the most serious type and has the potential to spread throughout the body. Exposition to the sun is responsible for most skin cancer cases. However, how much time you spend out in the sun doesn't tell you how likely you are to get skin cancer. It's your skin's appearance. The test SkinVisionAn app that monitors the skin for signs and changes offers a quick and easy method to determine y...

STOCKHOLM , Nov. 18, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR)  today announces that results from the investigator-initiated phase II clinical study in patients with squamous cell carcinoma (SCC) has been published in JAMA Dermatology by Kilgour, JM et al (doi:10.1001/jamadermatol.2021.4549). The primary objective of the study was to assess the effects of topical remetinostat on biopsy-proven SCC and SCC in situ tumors. This clinical study was conducted at the Stanford University School of Medicine in California, USA under the leadership of the principal investigator, Dr Kavita Sarin . Medivir is providing remetinostat drug supply for this study, and has full access to, and the rights to use, all clinical data after the study is complete. Four patients with five biopsy-proven cutaneous SCCs were included in this case series and treated with remetinostat gel 1%. All five tumours, including a range of histological subtypes, demonstrated complete clinical and...